Search Videos and More
News
Online Testing Tool Identifies People Likely to Benefit from Genetic Testing for Inherited Risk for Certain Cancers
An online tool developed by researchers and physicians at Dana-Farber Cancer Institute can accurately and rapidly identify people who should undergo testing for inherited genetic changes that raise the risk of developing certain cancers, a new study shows.
News
Bispecific Antibodies Continue the Promise of Immunotherapy
Until recently, when adults with acute lymphocytic leukemia (ALL) weren't cured or put into prolonged remission by standard chemotherapy, "there really was no good treatment option," says Marlise Luskin, MD, MSCE, a leukemia specialist at Dana-Farber Cancer Institute.
News
The Power of Plus: Combining Immunotherapy With Other Treatments is Showing Great Promise Against a Variety of Cancers
Even heroes need partners. As researchers are discovering, immunotherapy — the avatar of a new approach to cancer treatment — often works better when paired with other types of therapy.
News
Dana-Farber Research Publications
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Document
ESMO Congress 2022 Preview
Preview Studies and Symposia Featuring Dana-Farber Faculty
Document
Identification & Management of Lynch Syndrome in Clinical Practice
This conference will educate attendees on state-of-the-art approaches to managing individuals with known or suspected Lynch syndrome, a common, inherited form of cancer predisposition.
News
New Breast Cancer Clinical Trials
In the Breast Oncology Program at Dana-Farber Brigham Cancer Center, we offer breast cancer patients access to more than 50 clinical trials at a time — many of which are changing the standard of care worldwide and are not available elsewhere. We offer clinical trials for patients at all stages of their cancer journey, in the curative and metastatic settings, and welcome patients with any stage or subtype of disease.
News
2022 Master Class for Oncologists
Register here for the latest practices and guidelines in medical oncology. We look forward to bringing learners together again with expert faculty presentations and interactive panel discussions.
Video
Multiple Myeloma Research: Risks, Benefits of Stem Cell Transplant
Dana-Farber research into autologous stem cell transplant for patients with multiple myeloma: study led by Dr. Paul G. Richardson, MD, found patients had dramatically increased progression-free survival, but were just as likely to be alive more than 6 years later if they chose to reserve their transplant until later.
News
Monica Bertagnolli Named New Director of National Cancer Institute
Today, President Joe Biden announced that he is appointing Monica Bertagnolli, MD, surgical oncologist in the Dana-Farber Brigham Cancer Center and at Brigham and Women’s Hospital and member of the Gastrointestinal and Sarcoma Treatment Centers at Dana-Farber Cancer Institute, as director of the National Cancer Institute (NCI).
News
U.S. News & World Report Names Dana-Farber Brigham Cancer Center Among Nation's Best For 2022-2023
For the 22nd consecutive year, Dana-Farber Brigham Cancer Center has been recognized as a Best Hospital for cancer care by U.S. News & World Report. This year, Dana-Farber Brigham Cancer Center is ranked as the best hospital for cancer care in New England and #4 in the nation.
Video
ASCO2022: Multiple Myeloma Research by Dr. Paul Richardson
Dana-Farber research into autologous stem cell transplant for patients with multiple myeloma: a study led by Dr. Paul G. Richardson, MD, found patients had dramatically increased progression-free survival, but were just as likely to be alive more than 6 years later if they chose to reserve their transplant until later.